07:54 AM EDT, 07/29/2025 (MT Newswires) -- Incyte ( INCY ) reported Q2 non-GAAP earnings Tuesday of $1.57 per diluted share, swinging from an adjusted loss of $1.82 per share a year earlier.

Analysts surveyed by FactSet expected $1.40.

Revenue for the quarter ended June 30 was $1.22 billion, up from $1.04 billion a year earlier.

Analysts surveyed by FactSet expected $1.15 billion.

The company revised its guidance for its main product Jakafi (ruxolitinib) for full-year 2025 to $3 billion to 3.05 billion from $2.95 billion to $3 billion previously.

Analysts surveyed by FactSet expect $3.44 billion.

Incyte ( INCY ) shares were up 3.5% in recent premarket activity.